Account Info
Log Out
English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
STOCK ANALYSTS commented on a stock · Aug 19 13:11

SciSparc licenses SCI-160 pain drug program to Polyrizon. TIME TO BUY. SHOULD HIT 3 DOLLARS AND ABOVE. "STRONG BUY" RATING WITH MAX VALUE OF 520 DOLLARS

$SciSparc (SPRC.US)$ SciSparc licenses SCI-160 pain drug program to Polyrizon. TIME TO BUY. SHOULD HIT 3 DOLLARS AND ABOVE. "STRONG BUY" RATING WITH MAX VALUE OF 520 DOLLARS
SciSparc licenses SCI-160 pain drug program to Polyrizon. TIME TO BUY. SHOULD HIT 3 DOLLARS AND ABOVE. "STRONG BUY" RATING WITH MAX VALUE OF 520 DOLLARS
SciSparc licenses SCI-160 pain drug program to Polyrizon. TIME TO BUY. SHOULD HIT 3 DOLLARS AND ABOVE. "STRONG BUY" RATING WITH MAX VALUE OF 520 DOLLARS
SciSparc licenses SCI-160 pain drug program to Polyrizon. TIME TO BUY. SHOULD HIT 3 DOLLARS AND ABOVE. "STRONG BUY" RATING WITH MAX VALUE OF 520 DOLLARS
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
4
+0
Translate
Report
1814 Views
Comment
Sign in to post a comment
    avatar
    STOCK ANALYSTS
    47Followers
    0Following
    386Visitors
    Follow